Anthrasil Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Anthrasil market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historical period can be attributed to the heightened awareness of bioterrorism threats, the emergence of new anthrax cases, increased military preparedness efforts, growing awareness of veterinary health, and the rising incidence of anthrax in livestock.

The projected growth in the forecast period is driven by the increasing incidence of anthrax infections, expanding veterinary vaccination initiatives, the growing global trade in biologics, a heightened focus on public health preparedness, and intensified awareness and educational campaigns. Key trends expected in the forecast period include advancements in vaccine delivery systems, the development of more stable formulations, the integration of advanced analytics, improvements in monitoring and surveillance systems, and increased collaboration with biotech companies.

The increasing prevalence of anthrax infections is anticipated to drive the growth of the anthrasil market in the coming years. Anthrax, caused by the bacterium Bacillus anthracis, is transmitted through skin contact, inhalation, or ingestion, resulting in severe symptoms depending on the route of exposure. The rise in anthrax cases is linked to factors such as heightened exposure to infected animals, insufficient veterinary oversight, and socio-economic barriers to effective disease control and prevention. This growing incidence has led to increased utilization of anthrasil, as it provides immediate passive immunity and enhances survival rates in infected individuals. For example, the World Health Organization (WHO) reported in December 2023 that suspected anthrax cases in Zambia rose significantly, from 42 cases between September 2022 and January 2023 to 684 cases by November 20, 2023, across 44 districts in nine provinces, with a case fatality rate of 0.6% (four deaths). These trends underline the role of rising anthrax infections in driving demand for anthrasil.

A key trend in the anthrasil market is the emphasis on innovative vaccine development techniques, particularly cell-free filtrate technology, aimed at enhancing efficacy, improving safety profiles, and addressing emerging bioterrorism threats. This technology utilizes non-living components from an avirulent strain of Bacillus anthracis, minimizing the risk of adverse reactions while still effectively stimulating the immune system. For example, in July 2023, Emergent BioSolutions Inc., a U.S.-based biopharmaceutical company specializing in vaccines and antibody therapeutics for infectious diseases, received approval from the U.S. Food and Drug Administration (FDA) for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted). This vaccine marks a significant advancement in anthrax vaccination, incorporating the CPG7909 adjuvant to enhance the immune response, potentially leading to faster and stronger antibody production against Bacillus anthracis. CYFENDUS is made from cell-free filtrates of an avirulent strain of B. anthracis, ensuring it contains no live or dead bacteria, which reduces the risk of adverse reactions typically associated with traditional vaccines containing whole organisms.

In August 2024, Bora Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired a US sterile manufacturing facility from Emergent BioSolutions for an undisclosed amount. This acquisition strengthens Bora Pharma’s biotechnology and pharmaceutical capabilities, enhancing its contract development and manufacturing organization (CDMO) portfolio. Emergent BioSolutions, the manufacturer of anthrasil, continues to play a pivotal role in the anthrasil market.

The key players operating in the anthrasil market is Emergent BioSolutions Inc.

North America was the largest region in the Anthrasil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anthrasil report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anthrasil market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anthrasil is an immune globulin derived from the plasma of humans vaccinated against anthrax, used alongside antibiotics to treat inhalational anthrax in both adults and children. It functions by neutralizing anthrax toxins, thus preventing cellular damage and alleviating the infection's effects.

The primary forms of anthrasil are 60U and 100U. The 60U form contains anthrasil in 60-unit doses, intended for use in hospitals, clinics, and healthcare settings. Clinical indications include inhalational anthrax, neutralization of anthrax toxins, severe or systemic anthrax infections, preventing disease progression in high-risk groups, and post-exposure prophylaxis (PEP). The end users are hospital pharmacies, retail pharmacies, and others.

The anthrasil market research report is one of a series of new reports that provides anthrasil market statistics, including the anthrasil industry's global market size, regional shares, competitors with an anthrasil market share, detailed anthrasil market segments, market trends and opportunities, and any further data you may need to thrive in the anthrasil industry. This anthrasil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anthrasil market consists of sales of anthrasil (anthrax immune globulin intravenous - AIGIV), and anthrax vaccine adsorbed (AVA). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.